| 63.48 0 (0%) | 12-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 74.16 |
1-year : | 86.62 |
| Resists | First : | 63.5 |
Second : | 74.16 |
| Pivot price | 62.18 |
|||
| Supports | First : | 60.34 |
Second : | 58.38 |
| MAs | MA(5) : | 63.26 |
MA(20) : | 61.62 |
| MA(100) : | 60.15 |
MA(250) : | 56.95 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 97.8 |
D(3) : | 97 |
| RSI | RSI(14): 74.4 | |||
| 52-week | High : | 63.5 | Low : | 42.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CTLT ] has closed below upper band by 13.2%. Bollinger Bands are 71.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 63.57 - 63.91 | 63.91 - 64.19 |
| Low: | 62.63 - 63.02 | 63.02 - 63.35 |
| Close: | 62.85 - 63.5 | 63.5 - 64.06 |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Wed, 18 Dec 2024
Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent - Reuters
Wed, 18 Dec 2024
Catalent acquired by Novo Holdings for $16.5 billion - Investing.com
Fri, 06 Sep 2024
Decoding Catalent Inc (CTLT): A Strategic SWOT Insight - Yahoo Finance
Thu, 29 Aug 2024
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results - Business Wire
Wed, 08 May 2024
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results - Business Wire
Fri, 05 Apr 2024
Ares (ARES), Blue Owl Lead $4.8 Billion Private Debt for Catalent (CTLT) Deal - Bloomberg.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 182 (M) |
| Shares Float | 180 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 87.8 (%) |
| Shares Short | 14,740 (K) |
| Shares Short P.Month | 8,440 (K) |
| EPS | -2.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.52 |
| Profit Margin | -9.4 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | -11.2 % |
| Qtrly Rev. Growth | 4.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 24.35 |
| EBITDA (p.s.) | 2.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 399 (M) |
| Levered Free Cash Flow | 365 (M) |
| PE Ratio | -27.85 |
| PEG Ratio | 0 |
| Price to Book value | 3.25 |
| Price to Sales | 2.6 |
| Price to Cash Flow | 28.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|